Flexion Therapeutics Inc (FLXN) is Resumed by Wells Fargo to Outperform

Flexion Therapeutics Inc (FLXN) was Resumed by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on May 3, 2016.

Flexion Therapeutics Inc opened for trading at $10.42 and hit $10.7599 on the upside on Monday, eventually ending the session at $10.63, with a gain of 2.21% or 0.23 points. The heightened volatility saw the trading volume jump to 1,36,356 shares. Company has a market cap of $229 M.

In a different news, on Sep 14, 2015, C Ann Merrifield (director) purchased 1,000 shares at $23.00 per share price. According to the SEC, on Mar 16, 2015, Neil Bodick (Chief Medical Officer) sold 4,000 shares at $25.38 per share price.

Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.

Flexion Therapeutics Inc

Leave a Reply

Flexion Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Flexion Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.